If Form-based mode is enabled, the Questions will be available for answer in the right panel (red box); the Question under review has a **light blue background**, and all Questions should either be answered or marked "Not Relevant".

1/3

Nest Home Dashboard	Abstract Full Text Supplements Related Repo	rts		→ → Navigation ∧ Back Skip Complete
Settings	Q	🖉 🙀 🔖	5 G 5 G	€:
Literature Search				₹ Questions (3/11) ^
Other Sources				Study Conclusion: What were the study conclusions?
Duplicate Review Search Exploration Query Builder	Cancer Management a	nd Research	Dovepress open access to scientific and medical research	Annotate or Enter Text
Screening 4/4	Open Access Full Text Article		ORIGINAL RESEARCH	
ionfigure Screening	5-Eluorouraci	5-Fluorouracil, leucovorin, and oxaliplatin		
Tagging (0/4)		n lus sunitinih on l		Not Relevant Apply
Configure Tagging	(IIIFOLFOA6)	plus sunitinit or t	Devacizumad	Inclusion/Exclusion Criteria: What
	as first-line tro	eatment for metas	tatic colorectal	criteria?
Configure Extraction	🕴 cancer: a rand	lomized Phase IIb	study	Select Tag 🗸
Study Inspector	t un 14	This article was published in the following Dove Press jo Cancer Management and Research 15 June 2015 Number of times this article has been viewed	ournat	∠ Age
Manuscript Editor	udano			Enter Text
Abstract Editor	J Randolph Hecht	Background: Sunitinib is an oral inhibitor	of tyrosine kinase receptors implicated in tumor	
xport	Takayuki Yoshino ³	study, sunitinib plus mFOLFOX6 (oxaliplatir	plus leucovorin plus 5-fluorouracil) was compared	
	4 esn Manfred Welslau ⁴	with bevacizumab plus mFOLFOX6 as first- cancer	line therapy in patients with metastatic colorectal	₹ Tagging ∨
	Edna Chow Maneval ⁶	Methods: Patients were stratified by perform	nance status, baseline lactate dehydrogenase level,	
	Jolanda Paolini? Maria Jose Lechuga? Albrecht Kretzschmar ⁸ 'David Geffen School of Medicine at UCLA, Santa Monia, CA, 'Kilmined Caser: Center of Thomas	and prior adjuvant treatment, and randomize on and 2 weeks off plus mFOLFOX6 every 2 mFOLFOX6 every 2 weeks. The primary e endpoints included objective response rate, Results: Enrollment was closed early follor analysis showing an inferior trend in the point for emitting Mindex ic a patient week.	d 1:1 to receive summin 3:7.5 mg/day for 4 weeks weeks or bevacizationals 5 mg/kg/egvery 2 weeks plus adpoint was progression-free survival. Secondary overall survival, safety, and quality of life. wing accrual of 10 patients, based on an interim primary progression-free survival efficacy end- a conductivate of contribute plus mg/based based based based primary progression-free survival efficacy end- and the survival survival efficacy end- sorted based ba	₹² History ∨

All tags can still be added to the study using normal Tagging by expanding the Tagging panel (red arrow above).

Answering Questions

By adding Answers, you are applying the underlying tag, with the Tag Excerpt serving as the evidence that the correct Answer(s) have been added. The method of Answering depends on the type of Question, but for all Question types, the Tags applied will populate the Qualitative Synthesis in the same manner as Standard Tagging.

Note: Tag Recommendations are not available for Form-based Tagging mode.

Question Type-specific Answers

For each Question in the list, complete the following actions based on the type of Question:

• **Single Select:** Apply one child tag that answers the pre-configured questions. To do so, select one of the tags from the drop-down, and then highlight or select an Excerpt.

formanswer



• **Multi-Select:** Any of the child tags can be an answer, so you can apply as many tags from the drop-down as are applicable to the study. When all relevant child tags are added, select "Next" to mark the Question complete.

₹	Questions (0/41)	^		
Event category: What is the event category?				
\square	Intracranial hemorrhage 🗸 🗸			
2	right pons and			
Q	Blurred vision			
Ent	ter Text			
Ne	xt Apply			

• **Single Apply:** The tag under review is either applied to the study (select "Apply") or marked irrelevant. No child tags are added!



Whenever a Question has no relevant answers, select "Not Relevant" to move to the next Question.

What Answering a Question does

When a Question is finished (Applied or, for Multi-Select, when you select "Next"), or when the Question is marked Not Relevant, the count of completed Questions at the top of the right panel will update.

When all Questions are finished, you can either add tags using the Standard method (by opening the Tagging panel), or you can move to the next study by selecting "Complete" in the upper right-hand corner.

From: https://wiki.nested-knowledge.com/ - Nested Knowledge

Permanent link: https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:tagging:formanswer&rev=1668921594

Last update: 2022/11/20 05:19